Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemcentinib in recurrent glioblastoma
NCT03965494Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemcentinib in glioblastoma (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2020; status: terminated.
02
Drugs
bemcentinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03965494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965494.